-
Product Insights
Aveo Group – Aveo Carindale Retirement Facility – Queensland
Equip yourself with the essential tools needed to make informed and profitable decisions with our Aveo Group - Aveo Carindale Retirement Facility - Queensland report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...
-
Product Insights
Aveo Group/ Mulpha Australia – Norwest Quarter Mixed-Use Development – New South Wales
Equip yourself with the essential tools needed to make informed and profitable decisions with our Aveo Group/ Mulpha Australia - Norwest Quarter Mixed-Use Development - New South Wales report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full...
-
Company Profile
![]()
AVEO Pharmaceuticals Inc – Company Profile
AVEO Pharmaceuticals Inc (AVEO), is a biopharmaceutical company that focuses on the discovery, development, and commercialization of drugs for the treatment of various types of cancers. Its flagship product tivozanib is approved as a first line treatment for adult patients with renal cell carcinoma and marketed under the brand name Fotivda in European Union, Iceland and Norway. The company’s clinical product includes Ficlatuzumab, a hepatocyte growth factor inhibitory antibody, and AV-203, an anti-ErbB3 monoclonal antibody. It also has pre-clinical products...
Add to Basket -
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HCP-1803 in Idiopathic (Essential) Hypertension
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. HCP-1803 in Idiopathic (Essential) Hypertension Drug Details: HCP-1803 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MSB-3163 in Acne Vulgaris
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MSB-3163 in Acne Vulgaris Drug Details: MSB-3163 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AV-380 in Cancer Anorexia-Cachexia Syndrome
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AV-380 in Cancer Anorexia-Cachexia Syndrome Drug Details: AV-380 is under development for treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BMB-101 in Seizures
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.BMB-101 in Seizures Drug Details:BMA-101 is under development for the treatment of undisclosed seizure disorder, Dravet...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Vaccine For Cocaine Addiction in Substance (Drug) Abuse
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Vaccine For Cocaine Addiction in Substance (Drug) Abuse Drug Details:The vaccine candidate (dAd5GNE) is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ABBVCLS-484 in Non-Small Cell Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.ABBVCLS-484 in Non-Small Cell Lung Cancer Drug Details:ABBVCLS-484 is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GC-101 in Cervical Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.GC-101 in Cervical Cancer Drug Details:GC-101 is under development for the treatment of gastrointestinal tumors, epidermolysis...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BRL-601 in Castration-Resistant Prostate Cancer (CRPC)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.BRL-601 in Castration-Resistant Prostate Cancer (CRPC) Drug Details:BRL-601 is under development for the treatment of refractory...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – OBI-833 + OBI-821 in Esophageal Squamous Cell Carcinoma (ESCC)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Obi-833 + Obi-821 in Esophageal Squamous Cell Carcinoma (ESCC) Drug Details:OBI-833/821 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HFB-200603 in Colorectal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.HFB-200603 in Colorectal CancerDrug Details:HFB-200603 is under development for the treatment of solid tumor, renal cell...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – STT-003 in Melanoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. STT-003 in Melanoma Drug Details: STT-003 is under development for the treatment of head...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – STT-003 in Colon Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. STT-003 in Colon Cancer Drug Details: STT-003 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – KT-333 in Cutaneous T-Cell Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.KT-333 in Cutaneous T-Cell Lymphoma Drug Details:KT-333 is under development for the treatment of peripheral T...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Lipocurc in Prostate Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Lipocurc in Prostate Cancer Drug Details:Liposomal curcumin is under development for the treatment of metastatic cancer,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AV-203 in Peritoneal Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AV-203 in Peritoneal Tumor Drug Details: AV-203 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AV-203 in Skin Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AV-203 in Skin Cancer Drug Details: AV-203 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AV-203 in Neuroendocrine Tumors
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AV-203 in Neuroendocrine Tumors Drug Details: AV-203 is under development for the treatment of...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.